Pleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor prognosis. For almost two decades, the world standard treatment regimen for unresectable PM has consisted of a platinum-based drug plus pemetrexed, leading to an overall survival of approximately 12 months. The dramatic therapeutic scenario of PM has recently changed with the entry into the clinic of immune checkpoint inhibition, which has proven to be an effective approach to improve the survival of PM patients. The aim of the present review is to provide a comprehensive overview of the most promising immunotherapeutic-based strategies currently under investigation for advanced PM.

Calabrò, L., Bronte, G., Grosso, F., Cerbone, L., Delmonte, A., Nicolini, F., et al. (2024). Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream. FRONTIERS IN IMMUNOLOGY, 14 [10.3389/fimmu.2023.1333661].

Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream

Di Giacomo A. M.;Covre A.;Lofiego M. F.;
2024-01-01

Abstract

Pleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor prognosis. For almost two decades, the world standard treatment regimen for unresectable PM has consisted of a platinum-based drug plus pemetrexed, leading to an overall survival of approximately 12 months. The dramatic therapeutic scenario of PM has recently changed with the entry into the clinic of immune checkpoint inhibition, which has proven to be an effective approach to improve the survival of PM patients. The aim of the present review is to provide a comprehensive overview of the most promising immunotherapeutic-based strategies currently under investigation for advanced PM.
2024
Calabrò, L., Bronte, G., Grosso, F., Cerbone, L., Delmonte, A., Nicolini, F., et al. (2024). Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream. FRONTIERS IN IMMUNOLOGY, 14 [10.3389/fimmu.2023.1333661].
File in questo prodotto:
File Dimensione Formato  
Calabrò L Front in Immunol 2024.pdf

accesso aperto

Descrizione: Articolo
Tipologia: PDF editoriale
Licenza: Creative commons
Dimensione 1.37 MB
Formato Adobe PDF
1.37 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1276532